Prudentix was established by entrepreneurs with a 20-year track record of founding successful pharmaceutical and medical companies.
Our Experience
Founders
An MBA pharmacist with over 20 years of experience in pharmaceutical entrepreneurship and a track-record of co-founding and managing successful firms such as Tree of Life Pharma Ltd. and Prudentix Ltd.
Dr. Segal has over 20 years of entrepreneurship experience and a track-record as co-founder and CEO of successful firms such as Panaxia Pharmaceutical Industries Ltd. (Pharmaceutical cannabis products) and Luminera-Derm Ltd. (injectable dermal fillers).
Dr. Segal earned his doctorate in Computational Chemistry and Masters in Bioinformatics at the Weizmann Institute in Rehovot Israel.
An MBA pharmacist with 20 years of experience in the regulatory affairs field of medical devices and pharmaceuticals. Co-founder of several medical companies. Mr. Rosenbaum has been working for many years as a regulatory consultant of medical devices and pharmaceuticals.
Dr. Sacks brings over 18 years of experience in R&D and medical device development, from the stage of raw materials to pre-clinical and clinical studies. Before joining Planeeria, Dr. Sacks served as VP of R&D at PhytoTech Therapeutics (cannabinnoids derived Rx oral drugs), Director of Pharmaceutical R&D at Nicast (medical devices made of electrospun polymer nanofabrics), and in lead positions at TransPharma Medical (a combination drug-device transdermal delivery).
Prof. David Polak is a lecturer at the dept. of periodontology at the Hebrew University Hadassah Faculty of Dental Medicine .He graduated from the Hebrew University-Hadassah Faculty of Dental Medicine in 2004 and completed the graduate program in Periodontics in 2010 at the same institution and holds an EFP periodontist credential.
Currently, Dr. Polak is a senior instructor and researcher in basic science at the Department of Periodontology, Hadassah medical center.
His studies focus mainly on the pathogenesis of periodontal disease and neutrophil biology. Additional studies focus on biofilm models on teeth and implant surfaces as well as on the biology of osteoblast in processes of re-osseointegration in peri-implantitis models. Dr. Polak received several awards for his scientific and clinical achievements. He has published extensively in the dental and periodontal literature and is an invited speaker in national and international conferences.
Scientific Team
Senior orthopedic surgeon, subspecializing in foot and ankle surgery, Orthopedic Surgery Department, Hadassah University Hospital, Ein Kerem, Jerusalem, Israel. Dr. Haze’s PhD dissertation focused on the roles of amelogenins during the development and the regeneration of mesenchymal tissues (bone, cartilage and periodontal ligament). Dr. Haze is a member of the American Orthopedic Foot and Ankle Society.
A molecular biologist and biochemist at Hadassah-Hebrew university in Jerusalem. Anat Blumenfeld completed her PhD in Biochemistry at the Hebrew University, and post-doctoral training in Neurogenetics at Harvard Medical School. She published over 60 scientific manuscripts, received high-ranking grants and instructed M.Sc. students. Her studies with Prof. Deutsch and Dr. Haze concentrate on the structure, function, distribution and expression of the amelogenins during development and in tissues, and its ability to regenerate hard tissues.
Dr. Sacks brings over 18 years of experience in R&D and medical device development, from the stage of raw materials to pre-clinical and clinical studies. Before joining Planeeria, Dr. Sacks served as VP of R&D at PhytoTech Therapeutics (cannabinnoids derived Rx oral drugs), Director of Pharmaceutical R&D at Nicast (medical devices made of electrospun polymer nanofabrics), and in lead positions at TransPharma Medical (a combination drug-device transdermal delivery).
Department of Oral Biology chairman (1994-2000), Professor emeritus Dan Deutsch completed his PhD and post-doctoral studies in Biochemistry and Oral Biology at Leeds University, England. He holds an academic position at the Hebrew University for the past 40 years. He directed 24 PhD students and numerous MSc students, and published over 100 scientific manuscripts. For the past 25 years, he has been studying the structure, function, distribution and expression of amelogenin and its ability to regenerate hard tissues.
Prof. David Polak is a lecturer at the dept. of periodontology at the Hebrew University Hadassah Faculty of Dental Medicine .He graduated from the Hebrew University-Hadassah Faculty of Dental Medicine in 2004 and completed the graduate program in Periodontics in 2010 at the same institution and holds an EFP periodontist credential.
Currently, Dr. Polak is a senior instructor and researcher in basic science at the Department of Periodontology, Hadassah medical center.
His studies focus mainly on the pathogenesis of periodontal disease and neutrophil biology. Additional studies focus on biofilm models on teeth and implant surfaces as well as on the biology of osteoblast in processes of re-osseointegration in peri-implantitis models. Dr. Polak received several awards for his scientific and clinical achievements. He has published extensively in the dental and periodontal literature and is an invited speaker in national and international conferences.